Key Points
- uniQure Director Robert Gut sold 25,613 shares on Jan. 12 at an average price of $24.62 for $630,592, reducing his holding by 44.19% to 32,342 shares.
- The company reported quarterly EPS of -$1.38 (vs. -$0.85 expected) and revenue of $3.7M (vs. $4.46M expected), leaving uniQure with deeply negative margins and a negative PE.
- Analyst sentiment is largely positive—ten Buys, two Holds, one Sell—with an average price target of $60.82, and institutional investors own roughly 78.8% of the shares.
uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Robert Gut sold 25,613 shares of the business's stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Robert Gut also recently made the following trade(s):
- On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The stock was sold at an average price of $27.26, for a total value of $856,890.84.
uniQure Stock Up 4.0%
NASDAQ QURE opened at $22.35 on Thursday. The business's fifty day simple moving average is $24.98 and its 200-day simple moving average is $27.69. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.39 billion, a PE ratio of -5.09 and a beta of 0.68. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50.
uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million during the quarter, compared to analysts' expectations of $4.46 million. As a group, equities analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently commented on QURE. Stifel Nicolaus decreased their price objective on uniQure from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, December 11th. Guggenheim upped their price target on uniQure from $28.00 to $95.00 and gave the company a "buy" rating in a research note on Thursday, September 25th. UBS Group set a $95.00 price target on uniQure in a report on Thursday, September 25th. HC Wainwright cut their price objective on uniQure from $110.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, November 4th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $53.00 target price on shares of uniQure in a research report on Thursday, December 4th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $60.82.
View Our Latest Stock Report on QURE
Institutional Investors Weigh In On uniQure
A number of institutional investors have recently modified their holdings of QURE. Private Trust Co. NA purchased a new stake in shares of uniQure in the 3rd quarter valued at $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new stake in uniQure during the third quarter worth about $50,000. FNY Investment Advisers LLC lifted its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.
About uniQure
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
